Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD ) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
(Nasdaq: PAVM ), today announced the release of new real-world data from its ENVET-BE study supporting the clinical utility of the EsoGuard ® Esophageal DNA test as a non-invasive triage tool to significantly increase the positive yield of invasive upper endoscopy (EGD) for detection of esophageal precancer (Barrett's Esophagus or BE) and cancer. The manuscript entitled Enhancing the Positive Predictive Value of EGD for Diagnosis of Barrett's Esophagus Through EsoGuard ® Triage , is currently available on the leading health sciences preprint server, MedRxiv , while undergoing peer review for publication. Patients triaged to invasive EGD following a positive non-invasive EsoGuard test had a 2.
4-fold increase in the positive yield of those EGDs compared to the expected yield of screening EGD alone in at-risk patients. "Up to 90% of esophageal cancer patients were never previously diagnosed with esophageal precancer," said ENVET-BE investigator Jayde E. Kurland , M.
D., FACG, AGAF, a gastroenterologist and advanced endoscopist at Gastro Health in Lima , OH. "We found we were missing ~80% of patients in our busy endoscopy practice who sho.